Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Bumrungrad Hospital Public Company Limited
BZ7ABumrungrad Hospital Public Company Limited owns and operates healthcare-related entities in Thailand and internationally. It operates allergy, arrhythmia, behavioral health, breast, home service, heart valve, robotic surgery, rehabilitation, children's, colorectal surgery, complex coronary artery intervention, cornea transplant, dental, diagnostic, dialysis, digestive disease, ear, nose, throat, emergency, endocrinology, diabetes, expatriate liaison, eye, fertility, gastrointestinal motility, health screening, holistic wound care, horizon regional cancer, hyperbaric oxygen therapy, nephrology, neuroscience, orthopedics, perinatal, plastic surgery, pulmonary, refractive surgery, robotic scoliosis, skin, sports medicine and joint, surgery, travel medicine, urology, scientific wellness, skin and aesthetic, and women's centers. The company also operates breastfeeding, Yangon, COVID-19 recovery, comprehensive sleep, IVF, hearing and balance, medical, memory, new life healthy aging, Parkinson's disease and movement disorders, pride, surgery, vaccine clinics. In addition, it provides spine institute, diagnostic radiology and nuclear medicine, esperance, heart institute, intensive care unit, neurocritical care, nutrition services, pharmacy services, and preventive genomics and integrative medicine services. Further, the company offers clinical research; hospital consulting and management; healthcare personnel development and training; healthcare referral; and digital platform services. Additionally, it is involved in the distribution of pharmaceutical and medical goods in specialized stores; development of software for healthcare services; holding of real estate assets; and manufacture and sale of vitamin supplements. Bumrungrad Hospital Public Company Limited was founded in 1975 and is based in Bangkok, Thailand. Address: 33 Sukhumvit Soi 3 (Nana Nua), Bangkok, Thailand, 10110
Analytics
Precio Objetivo de WallStreet
–Relación P/E
30.4167Rentabilidad por dividendo
1.82 %Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave BZ7A
Análisis de dividendos BZ7A
Aumento del dividendo durante 5 años
32 %Crecimiento continuo
2 añoRatio de pago medio en 5 años
136 %Tendencia del payout BZ7A
Valoración de la acción BZ7A
Finanzas BZ7A
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |